EAACI IG Biologicals task force paper on the use of biologic agents in allergic disorders
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Biologic agents (also termed biologicals or biologics) are therapeutics that are synthesized by living organisms and directed against a specific determinant, for example, a cytokine or receptor. In inflammatory and autoimmune diseases, biologicals have revolutionized the treatment of several immune‐mediated disorders. Biologicals have also been tested in allergic disorders. These include agents targeting IgE; T helper 2 (Th2)‐type and Th2‐promoting cytokines, including interleukin‐4 (IL‐4), IL‐5, IL‐9, IL‐13, IL‐31, and thymic stromal lymphopoietin (TSLP); pro‐inflammatory cytokines, such as IL‐1β, IL‐12, IL‐17A, IL‐17F, IL‐23, and tumor necrosis factor (TNF); chemokine receptor CCR 4; and lymphocyte surface and adhesion molecules, including CD 2, CD 11a, CD 20, CD 25, CD 52, and OX 40 ligand. In this task force paper of the Interest Group on Biologicals of the European Academy of Allergy and Clinical Immunology, we review biologicals that are currently available or tested for the use in various allergic and urticarial pathologies, by providing an overview on their state of development, area of use, adverse events, and future research directions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structure and signalling in the IL-17 receptor family
Gaffen, S. L. (2009) · Nature reviews. Immunology · doi:10.1038/nri2586 · Cited by 1,475 · cited 2×
“All three dimers bind to receptor multimers composed of IL-17RA and IL17RC (12).”
BackgroundOmalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma
Gevaert, P., Calus, L., Van Zele, T., Blomme, K., De Ruyck, N., Bauters, W., Hellings, P., Brusselle, G., De Bacquer, D., van Cauwenberge, P., et al. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.07.047 · Cited by 744
Mepolizumab, a humanized anti–IL-5 mAb, as a treatment option for severe nasal polyposis
Gevaert, P., Van Bruaene, N., Cattaert, T., Van Steen, K., Van Zele, T., Acke, F., De Ruyck, N., Blomme, K., Sousa, A. R., Marshall, R. P., et al. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.07.056 · Cited by 629
Casale, T. B. (2001) · JAMA · doi:10.1001/jama.286.23.2956 · Cited by 377
Casale, T. B., Busse, W. W., Kline, J. N., Ballas, Z. K., Moss, M. H., Townley, R. G., Mokhtarani, M., Seyfert-Margolis, V., Asare, A., Bateman, K., et al. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.09.036 · Cited by 355 · cited 14×
“A RCT (n = 536) assessed the efficacy of omalizumab on symptoms of SAR in 25 centers in the USA (84).”
BackgroundMethodInfluentialKuehr, J., Brauburger, J., Zielen, S., Schauer, U., Kamin, W., Von Berg, A., Leupold, W., Bergmann, K.-C., Rolinck-Werninghaus, C., Gräve, M., et al. (2002) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2002.121949 · Cited by 342 · cited 1×
“A third study (n = 221), conducted in children aged 6–17 years, contained four treatment arms, including birch allergen SIT, grass allergen SIT, birch allergen SIT plus omalizumab, and grass allergen SIT plus omalizumab (91).”
BackgroundOldhoff, J. M., Darsow, U., Werfel, T., Katzer, K., Wulf, A., Laifaoui, J., Hijnen, D. J., Plötz, S., Knol, E. F., Kapp, A., et al. (2005) · Allergy · doi:10.1111/j.1398-9995.2005.00791.x · Cited by 339 · cited 1×
“IL-5: Mepolizumab (phase 2 completed) In a RCT in AD patients (n = 43), two single doses of 750 mg mepolizumab, given 1 week apart, caused a significant decrease in blood eosinophils and, to a lesser extent, tissue eosinophils (144, 145).”
BackgroundSelf-citationSafety of extended treatment with anakinra in patients with rheumatoid arthritis
Fleischmann, R. M., Tesser, J., Schiff, M. H., Schechtman, J., Burmester, G.-R., Bennett, R., Modafferi, D., Zhou, L., Bell, D., & Appleton, B. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.048371 · Cited by 305
Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome
Kim, S., Marigowda, G., Oren, E., Israel, E., & Wechsler, M. E. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.03.028 · Cited by 280
Massanari, M., Nelson, H., Casale, T., Busse, W., Kianifard, F., Geba, G. P., & Zeldin, R. K. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.11.022 · Cited by 230 · cited 1×
“Moreover, the number of patients that reached the maintenance dose was higher in the group receiving omalizumab (28).”
Background
Cited by
Targeting cell signaling in allergic asthma
Athari, S. S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0079-0 · Cited by 312
Muraro, A., Lemanske, R. F., Hellings, P. W., Akdis, C. A., Bieber, T., Casale, T. B., Jutel, M., Ong, P. Y., Poulsen, L. K., Schmid-Grendelmeier, P., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.03.010 · Cited by 284
Self-citationEAACI Biologicals Guidelines—Recommendations for severe asthma
Agache, I., Akdis, C. A., Akdis, M., Canonica, G. W., Casale, T., Chivato, T., Corren, J., Chu, D. K., Del Giacco, S., Eiwegger, T., et al. (2021) · Allergy · doi:10.1111/all.14425 · Cited by 275
Self-citationOncostatin M and interleukin-31: Cytokines, receptors, signal transduction and physiology
Hermanns, H. M. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2015.07.006 · Cited by 263
Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders
Kaegi, C., Wuest, B., Schreiner, J., Steiner, U. C., Vultaggio, A., Matucci, A., Crowley, C., & Boyman, O. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01990 · Cited by 260
Self-citationNovel Biologicals for the Treatment of Allergic Diseases and Asthma
Tan, H.-T. T., Sugita, K., & Akdis, C. A. (2016) · Current Allergy and Asthma Reports · doi:10.1007/s11882-016-0650-5 · Cited by 68
Latest developments in allergic rhinitis in Allergy for clinicians and researchers
Ng, C. L., & Wang, D. Y. (2015) · Allergy · doi:10.1111/all.12782 · Cited by 21
Metadata
- Authors
- Boyman, O., Kaegi, C., Akdis, M., Bavbek, S., Bossios, A., Chatzipetrou, A., Eiwegger, T., Firinu, D., Harr, T., Knol, E., Matucci, A., Palomares, O., Schmidt‐Weber, C., Simon, H. ‐., Steiner, U. C., Vultaggio, A., Akdis, C. A., & Spertini, F.
- Venue
- Allergy
- Publisher
- Wiley
- Published
- 2015-04-24
- Volume
- 70
- Issue
- 7
- Pages
- 727-754
- ISSN
- 0105-4538 (ISSN-L)
- 1398-9995
- OpenAlex
- W2066466369
- Cited by
- 106
- References
- 14
- FWCI
- 12.75
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.